Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs iShares MSCI Japan ETF (EWJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs iShares MSCI Japan ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287 (market cap $39.89B), while iShares MSCI Japan ETF trades at $92.77. The key difference: iShares MSCI Japan ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | EWJ | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $491.22 | $96.97 |
52-Week Low | $278.09 | $71.69 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
EWJ, the iShares MSCI Japan ETF, trades at $94.55, up 1.1% today, with a bullish technical signal from moving averages. The fund tracks Japanese equities, facing currency headwinds as the yen weakens against the dollar. Recent news highlights potential FX intervention by Japanese authorities to support the yen, which could impact returns for USD-based investors. Technical indicators show support at $92 and resistance at $95, with neutral oscillators suggesting limited momentum.
The outlook for EWJ is mixed, with opportunities from Japan's domestic investment push and AI-driven stock gains, but risks include yen volatility and economic sensitivity. Investors should weigh currency-hedged options to mitigate FX drag, as structural reforms and pension fund shifts may offer long-term growth amid near-term uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →
